JYJennifer K. Yee

Jennifer K. Yee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer K. Yee has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Catherine S. Mao

    Division of Endocrinology, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, USA

    7 shared publications
  • Juan Vega

    Division of Endocrinology, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA, 1124 West Carson Street, Torrance, CA, 90502, USA

    3 shared publications
  • Mary E. Patterson

    Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, USA

    3 shared publications
  • Wai-Nang Paul Lee

    Metabolomics Core, UCLA Center of Excellence in Pancreatic Diseases, Harbor-UCLA Medical Center, Torrance, CA 90502, USA

    3 shared publications
  • Ashley Martin

    Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, USA

    2 shared publications
  • C S Mao

    Division of Pediatric Endocrinology, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

    2 shared publications

Latest Publications

  • Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis

    by Amy L. Christison, Roy Kim, Eileen King, Rashmi Sahay, Roohi Kharofa, Brooke R. Sweeney, Vidhu Thaker, Jared M. Tucker, Alaina P. Vidmar, Jennifer K. Yee, et al.

    Introduction: The national POWER registry of paediatric weight management programmes reported increased obesity medication (ObM) use in recent years. However, factors influencing ObM prescribing are not well understood. This study aimed to compare (1) clinical characteristics between youth prescribed ObMs and those who were not and (2) prescribing patterns among programmes. Methods: Data from youth aged 6–18 years seen at 12 POWER sites between 2018 and 2024 were analysed. Clinical and demographic variables were compared between ObM and non‐ObM groups using Fisher's exact test and logistic regression, adjusting for site. Site‐level prescribing patterns were assessed using χ 2 and Fisher's exact tests. Results: ObMs were prescribed to 927 of 4628 (20%) patients. Topiramate (37%) and metformin (43%) were the most prescribed. ObM patients were older [12–15 years aOR (CI) = 1.7 (1.4, 2.0); 16–18 years aOR (CI) = 1.6 (1.3, 2.0) vs. 6–11 years], had more severe obesity [Class 2 aOR (CI) = 1.6 (1.3, 2.2); Class 3 aOR (CI) = 2.9 (2.3, 3.8) vs. Class 1] and had more obesity related co‐morbidities, but demographic characteristics were not different. Higher prescribing programmes offered ObMs sooner and multiple ObMs more often. Conclusions: ObM prescribing was strongly associated with age, obesity severity and comorbidities, highlighting the need for prospective studies on earlier initiation to prevent disease progression.


  • Open Access

    Transient islet-antigen 2 positivity at diagnosis of diabetes during COVID-19 infection in an adolescent with a NEUROD1 variant: a case report

    by Jennifer K. Yee, Seerat Anand, Juan C. Sanabria, Catherine S. Mao

    Background: Increased incidence of type 1 and type 2 diabetes has been reported in association with the coronavirus disease 2019 pandemic. Little is known about the impact of coronavirus disease 2019 on the presentation of monogenic forms of diabetes. This case report describes diagnosis of the uncommon maturity onset diabetes of the young (neurogenic differentiation factor 1-maturity-onset diabetes of the young) after transient autoimmunity during coronavirus disease 2019 infection. Case presentation: A 19-year-old Mexican male with autism spectrum disorder was diagnosed with diabetes without ketoacidosis during metabolic screening laboratory testing. He tested positive for coronavirus disease 2019 with no respiratory symptoms. His hemoglobin A1c was 14.2%, and had elevated islet-antigen 2 antibody. His blood glucose responded rapidly to initial dietary reduction in carbohydrate intake without insulin initiation, with subsequent improvement in hemoglobin A1c to 7.4% 2 months later. Then, 2 years after diagnosis, his hemoglobin A1c was 6.0%, and repeat antibody testing was negative. He was taking lisinopril for microalbuminuria, but required no medications for glucose control. Genetic testing identified a variant of NEUR OD 1 c.514C > T, p.(Leu172Phe). His mother who was subsequently diagnosed with diabetes, underwent targeted variant testing and was found to have the same neurogenic differentiation factor 1 variant. Conclusions: Coronavirus disease 2019 possibly triggered transient autoimmunity, leading to the diagnosis of neurogenic differentiation factor 1-maturity-onset diabetes of the young diabetes. This is also the first description of the clinical features associated with this particular neurogenic differentiation factor 1 variant.

  • Open Access

    The Effect of Flavonoids and Topiramate on Glucose Carbon Metabolism in a HepG2 Steatosis Cell Culture Model: A Stable Isotope Study

    by Li Ma, Qing-Yi Lu, Shu Lim, Guang Han, Laszlo G. Boros, Mina Desai, Jennifer K. Yee

    Background: Insufficient treatment options are available for metabolic dysfunction-associated steatotic liver disease (MASLD). Flavonoids and topiramate have been studied for weight loss but need investigation into their effects on liver metabolism. This study’s aim was to examine the effects of flavonoids or topiramate on glucose metabolic carbon flux in a cell culture model of steatosis. Methods: Steatosis was induced in HepG2 cells through exposure to oleic acid (OA, 0.5 mml/L) conjugated to bovine serum albumin (2:1). Additionally, 50% U13C-glucose was supplied in the medium as a stable isotope tracer. Cells were treated with DMSO, 10 μM of naringenin, morin, silibinin, or topiramate (44 μM) for 72 h. A non-steatotic, untreated HepG2 cell control was included. Cell extracts were analyzed by gas chromatography/mass spectrometry and mass isotopomer distribution analysis for glycogen synthesis, de novo fatty acid synthesis, tricarboxylic acid (TCA) cycle activity, and ribose synthesis. Groups were compared by ANOVA with Tukey’s pair-wise testing. Results: Compared to untreated HepG2 controls, OA-exposed steatotic cells exhibited increased lipid accumulation by ORO staining (1.6-fold), enhanced palmitate de novo synthesis, reduced pyruvate carboxylase/pyruvate dehydrogenase (PC/PDH) ratio, and reduced ribose synthesis. Treatment with topiramate or silibinin ameliorated the lipid accumulation (1.3-fold) and mitigated enhancement of de novo synthesis. Morin-treated cells exhibited enhanced de novo synthesis but suppressed ribose synthesis. Conclusions: Potential mechanisms of reduced lipid accumulation by topiramate and silibinin may include suppression of palmitate de novo synthesis and a relative decrease in carbon flux through the PDH pathway. Further studies are needed on potential utility in MASLD based on their specific metabolic effects.


  • Algorithms for Treating Dyslipidemia in Youth

    by Grace K. Kim, Jennifer K. Yee, Nidhi Bansal

    Purpose of Review The goal of this article is to review algorithms for treating dyslipidemia in youth, discuss pitfalls, propose enhanced algorithms to address pitfalls, and consider future directions. Recent Findings The presence of modifiable and non-modifiable cardiovascular disease (CVD) risk factors during childhood is associated with CVD-related events in adulthood. Recent data has shown that childhood initiation of statin therapy in youth < 18 years of age with familial hypercholesterolemia reduces the risk of adult CVD. However, pediatric dyslipidemia remains undertreated in part due to a lack of primary health care providers with adequate understanding of screening guidelines and pediatric lipidologists with experience in treatment and follow-up of this unique population. Management algorithms have been published by the National Heart, Lung, and Blood Institute and American Heart Association as tools to empower clinicians to manage dyslipidemia. We propose enhanced algorithms, which incorporate recently approved pharmacotherapy to address the management gaps. Future algorithms based upon clinical risk scores may enhance treatment and improve outcomes. Summary Algorithms for dyslipidemia management which target youth < 18 years of age are tools which empower clinicians to manage dyslipidemia in this unique population. Enhanced algorithms may help address pitfalls. We acknowledge the need for further risk assessment tools in pediatrics for tailored dyslipidemia management.


  • Physical Activity Counseling and Documentation by Pediatric Residents in Primary Care: Before and After Introduction of the FITT Principle

    by Benjamin Grace, Candice Taylor Lucas, Rashmi Shetgiri, Krystal Cardenas, Giselle Perez de la Garza, Youngju Pak, Jennifer K. Yee

    Physician training on physical activity (PA) counseling in patient care is highly variable. The objective of this study was to improve PA counseling by pediatric residents through introduction of the four components of PA, called the FITT principle (frequency, intensity, time, type). Pediatric residents ( n =30) received lectures, curriculum content, and an electronic smart-phrase addressing PA in obesity, including the FITT principle. Surveys assessed resident attitudes, and chart reviews ( n = 423 over 16 months) identified evidence of PA counseling including FITT principle components preintervention and postintervention. Survey results showed positive attitudes and confidence regarding primary care provider roles in counseling on PA, with no differences postintervention. Chart reviews demonstrated increased documentation on PA frequency postintervention (pre 31.9% vs post 50.9%, P =.00006), but no significant changes in intensity, time or type. In conclusion, a focused PA curriculum promoted PA counseling by pediatric residents, with increased documentation of one component of the FITT principle.


  • The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia

    by Waleed Z. Butt, Jennifer K. Yee

    Purpose of Review Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also important in homozygous familial hypercholesterolemia (HoFH), additional measures such as apheresis may be needed. The purpose of this review is to identify non-statin medications to lower cholesterol that are available for children and adolescents as adjunctive therapy. Recent Findings Ezetimibe is commonly used as second-line pharmacotherapy for treatment of HeFH and HoFH. Colesevelam, a bile acid sequestrant, may be considered for adjunct therapy. Since 2015, the PCSK9 inhibitor evolocumab has been available for adolescents, and its FDA approval has now expanded to age 10 years. The ANGPTL3 inhibitor evinacumab has been approved for children age 12 years and older. A clinical trial for lomitapide is in progress. Summary Approvals for PCSK9 and ANGPTL3 inhibitors have expanded opportunities for children and adolescents with HeFH and HoFH to achieve lower LDL-C levels.


  • Low Oleic/Stearic Desaturation Index in Great Blue Herons (Ardea herodias) with Steatitis in Southern California, USA

    by Jennifer K. Yee, Christine M. Liu, Mary Platter-Rieger, Juanita K. Jellyman, Luan Nguyen, Hassan Ghani, Karen L. Herbst

    We explored differences between the adipose tissue fatty acid profiles of Great Blue Herons (Ardea herodias) with and without steatitis. Adipose tissue from birds with steatitis exhibited inflammatory cell infiltration, low abundance of oleic acid, and a lower oleic/stearic desaturation index compared with tissue from birds without steatitis.

  • Open Access

    Acute metabolic responses to high fructose corn syrup ingestion in adolescents with overweight/obesity and diabetes

    by Mary E. Patterson, Jennifer K. Yee, Paulin Wahjudi, Catherine S. Mao, Wai-Nang P. Lee